Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Rani Therapeutics Holdings (RANI) Research & Development (2020 - 2025)

Rani Therapeutics Holdings has reported Research & Development over the past 6 years, most recently at $4.9 million for Q4 2025.

  • Quarterly results put Research & Development at $4.9 million for Q4 2025, down 27.91% from a year ago — trailing twelve months through Dec 2025 was $20.2 million (down 24.28% YoY), and the annual figure for FY2025 was $20.2 million, down 24.27%.
  • Research & Development for Q4 2025 was $4.9 million at Rani Therapeutics Holdings, up from $3.2 million in the prior quarter.
  • Over the last five years, Research & Development for RANI hit a ceiling of $12.0 million in Q3 2021 and a floor of $3.2 million in Q3 2025.
  • Median Research & Development over the past 5 years was $7.5 million (2021), compared with a mean of $7.5 million.
  • Biggest five-year swings in Research & Development: surged 472.2% in 2021 and later crashed 47.81% in 2025.
  • Rani Therapeutics Holdings' Research & Development stood at $7.4 million in 2021, then skyrocketed by 40.03% to $10.4 million in 2022, then dropped by 26.77% to $7.6 million in 2023, then fell by 10.47% to $6.8 million in 2024, then fell by 27.91% to $4.9 million in 2025.
  • The last three reported values for Research & Development were $4.9 million (Q4 2025), $3.2 million (Q3 2025), and $5.5 million (Q2 2025) per Business Quant data.